Government-Owned Inventions; Availability for Licensing, 54270-54272 [E7-18774]
Download as PDF
<![CDATA[
54270
Federal Register / Vol. 72, No. 184 / Monday, September 24, 2007 / Notices
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: Quality of
Life Outcomes in Neurological
Disorders; Type of Information
Collection Request: New; Form Number:
NA; Need and Use of Information
Collection: In order to improve outcome
measurement in clinical trials of
neurological conditions, NINDS is
developing a health-related quality of
life (HRQL) measurement system for
major neurological diseases that affect
the United States population. This
measurement system must be consistent
enough across the selected conditions to
allow for cross-disease comparison, and
yet flexible enough to capture
condition-specific HRQL issues. The
primary end users of this measurement
system will be clinical trialists and
other clinical neurology researchers;
however the measurement system will
Number of
respondents
Type of respondents
also be appropriate for clinical practice.
The proposed information collection
will support psychometric testing of
HRQL item banks and testing of Spanish
translation of the final questionnaires.
Frequency of Response: Once; Affected
Public: Individuals; Type of
Respondent: Adults and children. The
annual reporting burden is shown in the
following table. There are no Capital
Costs, Operating Costs or Maintenance
Costs to report.
Frequency of
response
Average time
per response
Annual hour
burden
Adults ...............................................................................................................
Children ............................................................................................................
6000
3000
1
1
0.5
0.5
3,000
1,500
Totals ........................................................................................................
9000
........................
........................
4,500
rfrederick on PROD1PC67 with NOTICES
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points; (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Claudia Moy,
Program Director, Clinical Trials Group,
NINDS, NIH, Neuroscience Center, 6001
Executive Boulevard, Room 2214,
Bethesda, MD 20892, or call non-tollfree number 301–496–2789 or e-mail
your request, including your address to:
moyc@ninds.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: September 6, 2007.
Joellen Harper Austin,
Executive Officer, NINDS, National Institutes
of Health.
[FR Doc. E7–18772 Filed 9–21–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
14:43 Sep 21, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone:
301/496–7057; fax: 301/402–0220. A
signed Confidential Disclosure
Agreement will be required to receive
copies of the patent applications.
Method for Predicting and Detecting
Tumor Metastasis
Description of Technology: Detecting
cancer prior to metastasis greatly
increases the efficacy of treatment and
the chances of patient survival.
Although numerous biomarkers have
been reported to identify aggressive
tumor types and predict prognosis, each
biomarker is specific for a particular
type of cancer, and no universal marker
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
that can predict metastasis in a number
of cancers have been identified. In
addition, due to a lack of reliability,
several markers are typically required to
determine the prognosis and course of
therapy.
Available for licensing are
carboxypeptidase E (CPE) inhibitor
compositions and methods to prognose
and treat cancer as well as methods to
determine the stage of cancer. The
inventors discovered that CPE
expression levels increase according to
the presence of cancer and metastasis
wherein CPE is upregulated in tumors
and CPE levels are further increased in
metastatic cancer. This data has been
demonstrated both in vitro and in vivo
experiments and in liver, breast,
prostate, colon, and head and neck
cancers. Metastatic liver cells treated
with CPE siRNA reversed the cells from
being metastatic and arrested cells from
further metastasis. Thus, CPE as a
biomarker for predicting metastasis and
its inhibitors have an enormous
potential to increase patient survival.
Applications: Method to prognose
multiple types of cancer and determine
likelihood of metastasis; Compositions
that inhibit CPE such as siRNA; Method
to prevent and treat cancer with CPE
inhibitors.
Market: 600,000 cancer related deaths
in 2006; Global cancer market is worth
more than eight percent of total global
pharmaceutical sales; Cancer industry is
predicted to expand to $85.3 billion by
2010.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Y. Peng Loh (NICHD) et al.
Publication: Manuscript in
preparation.
Patent Status: U.S. Provisional
Application No. 60/885,809 filed 19 Jan
E:\FR\FM\24SEN1.SGM
24SEN1
Federal Register / Vol. 72, No. 184 / Monday, September 24, 2007 / Notices
rfrederick on PROD1PC67 with NOTICES
2007 (HHS Reference No. E–096–2007/
0–US–01); U.S. Provisional Application
No. 60/887,061 filed 29 Jan 2007 (HHS
Reference No. E–096–2007/1–US–01);
U.S. Provisional Application No. 60/
895,912 filed 20 Mar 2007 (HHS
Reference No. E–096–2007/2–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute for Child Health
and Human Development, Section on
Cellular Neurobiology, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize CPE as a biomarker for
predicting metastasis. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Methods of Determining the Prognosis
of Hepatocellular Carcinoma
Description of Technology:
Hepatocellular carcinoma (HCC)
represents an extremely poor prognostic
cancer that remains one of the most
common and aggressive malignancies
worldwide. A major hallmark of HCC is
intrahepatic metastasis and postsurgical reoccurrence. With current
diagnostic methods, HCC patients are
often diagnosed with end-stage cancer
and have poor survival. Thus, there is
a need for an accurate method to
identify HCC and its proclivity for
metastases/relapse, particularly at early
stages of this disease.
The inventors have discovered a
unique set of microRNA (miRNA)
biomarkers that are associated with HCC
metastasis/recurrence. This miRNA
signature was validated in an
independent cohort of 110 HCC samples
as an independent predictor of HCC
prognosis and likelihood of metastasis
and relapse. In particular, the inventors
provide evidence that these miRNA
markers can predict HCC metastasis in
the early stages of cancer. This
methodology may enable clinicians to
effectively stratify patients for
appropriate cancer treatment and
prioritize liver transplantation
candidates.
Applications: Method to prognose
HCC, patient survival and likelihood of
HCC metastasis/relapse; Diagnostic tool
to aid clinicians in determining
appropriate cancer treatment;
Compositions that inhibit miRNA HCC
biomarkers such as siRNA; Method to
treat HCC patients with inhibitory
miRNA compositions.
Market: Primary liver cancer accounts
for about 2% of cancers in the U.S., but
VerDate Aug<31>2005
14:43 Sep 21, 2007
Jkt 211001
up to half of all cancers in some
undeveloped countries; Post-operative
five year survival rate of HCC patients
is 30–40%.
Development Status: This technology
is currently in the pre-clinical stage of
development.
Inventors: Xin Wei Wang et al. (NCI).
Publication: Budhu et al. A Unique
Metastasis-related MicroRNA
Expression Signature Predicts Survival
and Recurrence in Hepatocellular
Carcinoma, manuscript in preparation.
Patent Status: U.S. Provisional
Application No. 60/884,052 filed 09 Jan
2007 (HHS Reference No. E–050–2007/
0–US–01).
Licensing Availability: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
54271
2006 (HHS Reference No. E–319–2006/
0–US–01).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute’s Urologic
Oncology Branch is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize models to study aging
and longevity factors. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Biomarkers for Tissue Status
Description of Technology: Tissue
regeneration and tumorigenesis are
complex, adaptive processes controlled
by cues from the tissue
Mutant Alleles of Hsp90 That
microenvironment. There are complex
Modulates the Lifespan of Yeast
Description of Technology: Heat shock processes both characterized by cell
proliferation, migration, and
protein 90 (Hsp90) are a class of
chaperone proteins that are up-regulated angiogenesis suggesting that wounds
in response to elevated temperature and and cancer share a number of
phenotypic similarities including
other environmental stresses. They act
cellular behavior, signaling molecules,
as chaperones to other cellular proteins
and gene expression.
and facilitate their proper folding and
Utilizing the kidneys as a model to
repair, and aid in the refolding of
compare renal regeneration and repair
misfolded client proteins.
(RRR) from ischemically-injured tissues
This invention identifies Hsp90
and renal cellular carcinoma (RCC), the
mutant residues that affect the
inventors have identified biomarkers
chronological lifespan of yeast. These
which are differentially expressed. The
mutations in addition to a deletion in
invention relates to methods of quickly
the sch9 allele, the yeast homolog to
and accurately diagnosing RCC and
human kinase AKT, can increase yeast
monitoring renal tissue health as well as
lifespan from 45 to 57 days,
RCC treatment.
approximately 20% longer than the
Applications: Method to accurately
wildtype strain. These genetically
diagnose RCC; RCC biomarker inhibitors
engineered yeast strains may have the
such siRNA; Method to treat RCC;
longest chronological lifespan reported
Method to determine and monitor renal
to date.
tissue health status; Method for
Applications: Model to study aging
improving renal ischemia recovery
and longevity factors; Model to screen
without promoting RCC; Biomarkers for
compounds that affect lifespan; A longimmunotherapy, drug targeting and
lived yeast strain could be used to
drug screening, for targeting tumors and
ferment alcohol in a more efficient and
not normal regenerating tissue;
cost effective as an alternative fuel
Biomarkers for immunotherapy, drug
source; Method to extend lifespan of
targeting and drug screening, for
transgenic farm animals.
targeting ischemic tissue and not
Market: Anti-aging and alternative
tumors.
fuel industries are worth billions of
Market: Kidney cancer is one of the
dollars.
top ten most prevalent cancers in the
Development Status: The technology
U.S. and it accounts for 12,200 deaths
is currently in the pre-clinical stage of
annually; Approximately 35,000 new
development.
cases of kidney cancer are diagnosed
Inventors: Bradley T. Scroggins (NCI)
annually; 50% survival rate after five
et al.
years of diagnosis; Renal cancer
Related Publication: BT Scroggins et
accounts for 3% of all adult male
al. An acetylation site in the middle
malignancies.
domain of Hsp90 regulates chaperone
Development Status: The technology
function. Mol Cell. 2007 Jan
is currently in the pre-clinical stage of
12;25(1):151–159.
development.
Patent Status: U.S. Provisional
Inventors: Joseph Riss (NCI) et al.
Publications:
Application No. 60/848,346 filed 09 Sep
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
E:\FR\FM\24SEN1.SGM
24SEN1
54272
Federal Register / Vol. 72, No. 184 / Monday, September 24, 2007 / Notices
1. FF Marshall. Urological Survey.
Urological Oncology: Renal, Ureteral
and Retroperitoneal Tumors. J Urol.
2007 May;177(5):1732–1734.
2. J Riss et al. Cancers as wounds that
do not heal: Differences and similarities
between renal regeneration/repair and
renal cell carcinoma. Cancer Res. 2006
July 15;66(14):7216–7224.
Patent Status: U.S. Provisional
Application No. 60/649,208 filed 01 Feb
2005 (HHS Reference No. E–064–2005/
0–US–01); PCT Application No. PCT/
US2006/003611 filed 01 Feb 2006 (HHS
Reference No. E–064–2005/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of Cancer
Biology and Genetics, Wound Healing
and Oncogenesis (NCI/CCR/LCBG), is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
topics of invention or related to cancer
biology, metastasis, wound healing,
bioinformatics, pharmacogenomics and
therapeutic. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: September 18, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–18774 Filed 9–21–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rfrederick on PROD1PC67 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
VerDate Aug<31>2005
14:43 Sep 21, 2007
Jkt 211001
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
A Transgenic Mouse Expressing
Reverse Tetracycline-Controlled
Transactivator in Melanocytes
Description of Technology: Available
for licensing are transgenic mice that
allow for specific and inducible
expression of proteins in melanocytes.
Melanocytes are difficult to study
because of their paucity in mammalian
skin, and these mice present a readily
available source of these cells and
model to study melanocyte diseases
such as melanoma of the skin and eye.
The mice can be crossed with transgenic
mice that harbor the green fluorescent
protein (GFP) gene, resulting in
melanocyte-specific GFP labeling. GFP
labeling can aid in imaging and/or
isolation of melanocytes via
fluorescence activated cell sorting, and
it can be used to study melanocytes at
both the cellular and molecular level.
Applications: Research tool to study
melanocytes and melanocyte related
diseases such as melanoma of the skin
and eye.
Model to develop and test cosmetic
dermatology products such as skin
tanners.
Advantages: Research tool to study
melanocytes at the cellular and
molecular level.
Melanocytes compose a minute
fraction of mammalian skin. These mice
present a significant advantage in
labeling, imaging and isolating these
cells.
Market: An estimated 59,940
Americans will be diagnosed with skin
cancer in 2007.
An estimated 8,110 Americans will
die of skin cancer in 2007.
Intraocular melanoma is a rare
disease. For every 100,000 Americans,
there are approximately 17.7 new cases
of intraocular melanoma.
Cosmetic dermatology industry is
worth billions of dollars.
Inventors: Glenn T. Merlino, M. Raza
Zaidi, et al. (NCI)
Publication: Planned oral presentation
at the Fourth International Congress on
Melanoma in New York City, November
1–4, 2007. The technology is mentioned
in the Abstract for this meeting.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Patent Status: HHS Reference No.
E–308–2007/0—Research Tool. Patent
protection is not being sought for this
technology.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Laboratory of Cancer Biology and
Genetics of the National Cancer Institute
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize use
of transgenic mice that allow for specific
and inducible expression of proteins in
melanocytes. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Chimeric Peptide Antigen Library: A
Novel Tool for the Development of
Vaccines Against Variable Pathogens
Such as HIV, Tuberculosis, Hepatitis C
and Malaria
Description of Technology: Many
pathogens of dangerous human diseases
such as HIV–1, HIV–2, viruses of
hepatitis B and C, virus of influenza,
viruses of dengue fever of types 1–4,
pathogens of malaria and tuberculosis
all possess significant variability.
Libraries of chimeric peptides, which
imitate the genetic variability of the
variable sections of the pathogenic
protein, can cause a defensive immune
response to the wide spectrum of the
pathogen diversity. The immunogenic
collections of chimeric peptides
(libraries of variable chimeric peptides)
in total reflect the natural and potential
variability of the sections which
determine antigenic activity.
The present invention relates to
antigenic peptides, the methods of their
preparation and their peptide libraries
and it can be used for preparation of
vaccines and medicine diagnostics.
More specifically, the invention
describes that the number of sequences
in the library (size of library) is equal to
the product of the number of possible
residues in each position of peptide.
The size of library can be reduced by
sequential removal of residues which
have the lowest frequency until the size
will reach the required value.
Applications: Variable chimeric
peptide libraries (VPCLs) can help
construct effective vaccines capable of
treating variable infectious agents such
as HIV, TB, and Malaria.
Advantages: VPCLs represent
naturally occurring and potential
variability of antigenically active
regions in one vaccine.
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 72, Number 184 (Monday, September 24, 2007)]
[Notices]
[Pages 54270-54272]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-18774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Method for Predicting and Detecting Tumor Metastasis
Description of Technology: Detecting cancer prior to metastasis
greatly increases the efficacy of treatment and the chances of patient
survival. Although numerous biomarkers have been reported to identify
aggressive tumor types and predict prognosis, each biomarker is
specific for a particular type of cancer, and no universal marker that
can predict metastasis in a number of cancers have been identified. In
addition, due to a lack of reliability, several markers are typically
required to determine the prognosis and course of therapy.
Available for licensing are carboxypeptidase E (CPE) inhibitor
compositions and methods to prognose and treat cancer as well as
methods to determine the stage of cancer. The inventors discovered that
CPE expression levels increase according to the presence of cancer and
metastasis wherein CPE is upregulated in tumors and CPE levels are
further increased in metastatic cancer. This data has been demonstrated
both in vitro and in vivo experiments and in liver, breast, prostate,
colon, and head and neck cancers. Metastatic liver cells treated with
CPE siRNA reversed the cells from being metastatic and arrested cells
from further metastasis. Thus, CPE as a biomarker for predicting
metastasis and its inhibitors have an enormous potential to increase
patient survival.
Applications: Method to prognose multiple types of cancer and
determine likelihood of metastasis; Compositions that inhibit CPE such
as siRNA; Method to prevent and treat cancer with CPE inhibitors.
Market: 600,000 cancer related deaths in 2006; Global cancer market
is worth more than eight percent of total global pharmaceutical sales;
Cancer industry is predicted to expand to $85.3 billion by 2010.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Y. Peng Loh (NICHD) et al.
Publication: Manuscript in preparation.
Patent Status: U.S. Provisional Application No. 60/885,809 filed 19
Jan
[[Page 54271]]
2007 (HHS Reference No. E-096-2007/0-US-01); U.S. Provisional
Application No. 60/887,061 filed 29 Jan 2007 (HHS Reference No. E-096-
2007/1-US-01); U.S. Provisional Application No. 60/895,912 filed 20 Mar
2007 (HHS Reference No. E-096-2007/2-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Institute for
Child Health and Human Development, Section on Cellular Neurobiology,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize CPE as a biomarker for predicting metastasis. Please
contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for
more information.
Methods of Determining the Prognosis of Hepatocellular Carcinoma
Description of Technology: Hepatocellular carcinoma (HCC)
represents an extremely poor prognostic cancer that remains one of the
most common and aggressive malignancies worldwide. A major hallmark of
HCC is intrahepatic metastasis and post-surgical reoccurrence. With
current diagnostic methods, HCC patients are often diagnosed with end-
stage cancer and have poor survival. Thus, there is a need for an
accurate method to identify HCC and its proclivity for metastases/
relapse, particularly at early stages of this disease.
The inventors have discovered a unique set of microRNA (miRNA)
biomarkers that are associated with HCC metastasis/recurrence. This
miRNA signature was validated in an independent cohort of 110 HCC
samples as an independent predictor of HCC prognosis and likelihood of
metastasis and relapse. In particular, the inventors provide evidence
that these miRNA markers can predict HCC metastasis in the early stages
of cancer. This methodology may enable clinicians to effectively
stratify patients for appropriate cancer treatment and prioritize liver
transplantation candidates.
Applications: Method to prognose HCC, patient survival and
likelihood of HCC metastasis/relapse; Diagnostic tool to aid clinicians
in determining appropriate cancer treatment; Compositions that inhibit
miRNA HCC biomarkers such as siRNA; Method to treat HCC patients with
inhibitory miRNA compositions.
Market: Primary liver cancer accounts for about 2% of cancers in
the U.S., but up to half of all cancers in some undeveloped countries;
Post-operative five year survival rate of HCC patients is 30-40%.
Development Status: This technology is currently in the pre-
clinical stage of development.
Inventors: Xin Wei Wang et al. (NCI).
Publication: Budhu et al. A Unique Metastasis-related MicroRNA
Expression Signature Predicts Survival and Recurrence in Hepatocellular
Carcinoma, manuscript in preparation.
Patent Status: U.S. Provisional Application No. 60/884,052 filed 09
Jan 2007 (HHS Reference No. E-050-2007/0-US-01).
Licensing Availability: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Mutant Alleles of Hsp90 That Modulates the Lifespan of Yeast
Description of Technology: Heat shock protein 90 (Hsp90) are a
class of chaperone proteins that are up-regulated in response to
elevated temperature and other environmental stresses. They act as
chaperones to other cellular proteins and facilitate their proper
folding and repair, and aid in the refolding of misfolded client
proteins.
This invention identifies Hsp90 mutant residues that affect the
chronological lifespan of yeast. These mutations in addition to a
deletion in the sch9 allele, the yeast homolog to human kinase AKT, can
increase yeast lifespan from 45 to 57 days, approximately 20% longer
than the wildtype strain. These genetically engineered yeast strains
may have the longest chronological lifespan reported to date.
Applications: Model to study aging and longevity factors; Model to
screen compounds that affect lifespan; A long-lived yeast strain could
be used to ferment alcohol in a more efficient and cost effective as an
alternative fuel source; Method to extend lifespan of transgenic farm
animals.
Market: Anti-aging and alternative fuel industries are worth
billions of dollars.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Bradley T. Scroggins (NCI) et al.
Related Publication: BT Scroggins et al. An acetylation site in the
middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007 Jan
12;25(1):151-159.
Patent Status: U.S. Provisional Application No. 60/848,346 filed 09
Sep 2006 (HHS Reference No. E-319-2006/0-US-01).
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute's
Urologic Oncology Branch is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize models to study aging and longevity
factors. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Biomarkers for Tissue Status
Description of Technology: Tissue regeneration and tumorigenesis
are complex, adaptive processes controlled by cues from the tissue
microenvironment. There are complex processes both characterized by
cell proliferation, migration, and angiogenesis suggesting that wounds
and cancer share a number of phenotypic similarities including cellular
behavior, signaling molecules, and gene expression.
Utilizing the kidneys as a model to compare renal regeneration and
repair (RRR) from ischemically-injured tissues and renal cellular
carcinoma (RCC), the inventors have identified biomarkers which are
differentially expressed. The invention relates to methods of quickly
and accurately diagnosing RCC and monitoring renal tissue health as
well as RCC treatment.
Applications: Method to accurately diagnose RCC; RCC biomarker
inhibitors such siRNA; Method to treat RCC; Method to determine and
monitor renal tissue health status; Method for improving renal ischemia
recovery without promoting RCC; Biomarkers for immunotherapy, drug
targeting and drug screening, for targeting tumors and not normal
regenerating tissue; Biomarkers for immunotherapy, drug targeting and
drug screening, for targeting ischemic tissue and not tumors.
Market: Kidney cancer is one of the top ten most prevalent cancers
in the U.S. and it accounts for 12,200 deaths annually; Approximately
35,000 new cases of kidney cancer are diagnosed annually; 50% survival
rate after five years of diagnosis; Renal cancer accounts for 3% of all
adult male malignancies.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Joseph Riss (NCI) et al.
Publications:
[[Page 54272]]
1. FF Marshall. Urological Survey. Urological Oncology: Renal,
Ureteral and Retroperitoneal Tumors. J Urol. 2007 May;177(5):1732-1734.
2. J Riss et al. Cancers as wounds that do not heal: Differences
and similarities between renal regeneration/repair and renal cell
carcinoma. Cancer Res. 2006 July 15;66(14):7216-7224.
Patent Status: U.S. Provisional Application No. 60/649,208 filed 01
Feb 2005 (HHS Reference No. E-064-2005/0-US-01); PCT Application No.
PCT/US2006/003611 filed 01 Feb 2006 (HHS Reference No. E-064-2005/0-
PCT-02).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Laboratory of Cancer Biology and Genetics,
Wound Healing and Oncogenesis (NCI/CCR/LCBG), is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize topics of
invention or related to cancer biology, metastasis, wound healing,
bioinformatics, pharmacogenomics and therapeutic. Please contact John
D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more
information.
Dated: September 18, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-18774 Filed 9-21-07; 8:45 am]
BILLING CODE 4140-01-P
